TEL: +86 571 56623320    EMAIL: [email protected]

Sunlong Biotech / 2026-10-30
Technical Q & A
SL2304Hu Human IFNβ-Ab ELISA ADA cutoff
ProductHuman Interferonβ Antibody (IFNβ-Ab)elisa Kit
Cat. No.SL2304Hu

Question

Since my study requires classifying patients as ADA-positive or ADA-negative before performing NAb testing, could you please advise how to establish a scientifically valid positivity cutoff for your quantitative IFN-β-Ab ELISA kit?

Do you have a recommended procedure using negative human serum samples, including the required number of samples and statistical method?

Answer

The scientifically reasonable approach to establishing the ADA positivity cutoff is as follows: negative serum samples from the patient population you plan to test (e.g., patients who have not received IFN-β treatment) must be used, and the screening cut point must be established in-house according to the statistical method recommended by the FDA immunogenicity testing guidance (90% one-sided lower confidence limit of the 95th percentile).

Specific operating steps:

1. Data collection: Use this ELISA kit to test at least 50 (120 recommended) negative human serum samples from the intended test population (duplicate wells are recommended; use the mean OD value or calculated concentration value as the response value for that sample).

2. Data distribution check: Perform a normality test on the collected negative sample response values. ADA test data in the negative population usually show a skewed distribution, so nonparametric methods are preferred.

3. Calculate the Cut Point:

Calculate the 95th percentile of the negative sample response values.

Calculate the 90% one-sided confidence interval of this 95th percentile, and take its lower limit as the final screening cut point.

Decision rule: When the response value of a patient sample to be tested is ≥ this cut point, it is determined to be ADA positive (screening positive); when it is below this value, it is determined to be negative.

4. (Optional) Validation and gray zone: You can use receiver operating characteristic (ROC) curve analysis to assist in validating the reasonableness of this cut point, or set a "gray zone" according to laboratory practice (e.g., ±20% of the cut point); gray zone samples are recommended to be retested for confirmation.

Notes

· Sample type: negative human serum samples from the patient population planned for testing (e.g., patients who have not received IFN-β treatment).

· Other specifications: Use this ELISA kit; at least 50 (120 recommended) negative human serum samples; it is recommended to run replicate wells and use the mean OD value or calculated concentration value as the response value; perform a normality test on the response values of negative samples, with non-parametric methods preferred; establish the screening cut point according to the lower limit of the 90% one-sided confidence interval of the 95th percentile; patient sample response values ≥ cut point are judged ADA positive, and those below this value are judged negative; optional ROC-assisted verification, or set a gray zone according to laboratory practice (e.g., ±20% of the cut point); retesting is recommended for confirmation of gray-zone samples.

For further technical support, contact [email protected]

User Comment(Total0User Comment Num)

  • No comment
Total 0 records, divided into1 pages First Prev Next Last
Username: Anonymous user
E-mail:
Rank:
Content:
Verification code: captcha

Call us

+86 571 56623320

Address

Room 1-315, Kongle Changqing Building, No. 160 Guangye Road,Gongshu District, Hangzhou City, Zhejiang Province, China

Join Us with

Leave a message
* To protect against spam, please pass the CAPTCHA test below.
© 2005-2026 SUNLONG BIOTECH CO., LTD Copyright, All Rights Reserved.